5. In early post-resection period, the functional insufficiency of the residual hepatocyte volume was reliably  
					higher in the group with concomitant chronic diffuse liver pathology, that results in prolongation of the period  
					of compensatory regeneration with normalization of the main biochemical blood parameters, on the average, on  
					day 16.5±0.7 vs.day11.3±0.4 in the group with no concomitant liver diseases.  
					6. Chronic diffuse process in the liver contributed to an increase in the risk of intra-operative blood loss in  
					segmental (P<0.01) and extensive (P<0.05) resections with an increase in the period of vascular isolation by  
					Pringle’s method from 19.8±1.3 min to 23.1±1.9 min and from 27.9±1.7 min to 34.5±2.1 min, respectively (P<0.05),  
					as well as surgery duration from 140±11 to 186±13 min (P<0.01) and from 228±14 min to 282± 16 min (P<0.05).  
					7. The risk of development of complications after resection performed to patients with concomitant chronic  
					diffuse process in the liver rises from 21.4% to 35.8% increasing mortality rate from 3.6% to 5.7% and average  
					duration of the hospital stay from 23.7±0.9 to 28.7±1.0 days (P<0.001).  
					DECLARATIONS  
					Acknowledgements  
					This work was supported by Republican Specialized Center of Surgery named after acad.V.Vakhidov.  
					Tashkent.  
					Authors’ Contributions  
					All authors contributed equally to this work.  
					Competing interests  
					The authors declare that they have no competing interests.  
					REFERENCES  
					1. Belghiti JJ (2009). Resection and liver transplantation for HCC. Gastroenterol., 44(Suppl 19): 132-135.  
					2. Bertens KA, Hawel J, Lung K, Buac S, Pineda-Solis K, Hernandez-Alejandro R. (2014). ALPPS: Challenging the concept of  
					unresectability - A systematic review. Int J Surg., 13C: 280-287.  
					3. Troja A, Khatib-Chahidi K, El-Sourani N, Antolovic D, Raab HR. (2014) ALPPS and similar resection procedures in treating  
					extensive hepatic metastases: our own experiences and critical discussion. Int. J. Surg., 12(9): 1020-1022.  
					4. Wu X, Li B, Qiu J, Shen J, Zheng Y, Li Q, Liao Y, He W, Zou R, Yuan Y. (2015). Hepatectomy versus hepatectomy with  
					lymphadenectomy in hepatocellular carcinoma: a prospective, randomized controlled clinical trial. World J.  
					Gastroenterol., 21(1): 246-253.  
					5. Colle I, Verhelst X, Vanlander A, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X, Troisi RI. (2013). Pathophysiology  
					and management of post resection liver failure. Acta Chir. Belg., 113(3): 155-161.  
					6. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. (2004). Risk  
					factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter  
					study. J. Surg. Oncol., 85(1): 36-41.  
					7. Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente  
					E, Concepcion AR, Medina JF, Marin JJ, Berasain C, Prieto J, Avila MA. (2013). Identification of fibroblast growth factor 15  
					as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut.,  
					62(6): 899-910.  
					8. Ishii M, Mizuguchi T, Harada K, Ota S, Meguro M, Ueki T, Nishidate T, Okita K, Hirata K. (2014). Comprehensive review of  
					post-liver resection surgical complications and a new universal classification and grading system. World J. Hepatol., 27;  
					6(10): 745-751.  
					9. Fuster J, Llovet JM, Garcia-Valdecasas JC, Grande L, Fondevila C, Vilana R, Palacin J, Tabet J, Ferrer J, Bruix J, Visa J.  
					(2004). Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized  
					controlled study. Hepatogastroenterology, 51(56): 536-540.  
					10. Curro G, Jiao L, Scisca C, Baccarani U, Mucciardi M, Habib N, Navarra G. (2008). Radio frequency-assisted liver  
					resection in cirrhotic patients with hepatocellular carcinoma. J. Surg. Oncol., 98(6): 407-410.  
					11. Lai Q, Avolio AW, Lerut J, Sin 8. Lai Q, Avolio AW, Lerut J, Singh G, Chan SC, Berloco PB, Tisone G, Agnes S, Chok KS,  
					Sharr W, Rossi M, Manzia TM, Lo CM. (2012). Recurrence of hepatocellular cancer after liver transplantation: the role of  
					primary resection and salvage transplantation in East and West. J. Hepatol., 57(5): 974-979.  
					12. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y,  
					Matsunaga T. (2014). Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined  
					JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. Dig. Dis., 32(6): 717-724.  
					Nazirov F.G., Akbarov M.M., Ibadov R.A., Khakimov Y.U., Sirojiddinov K.K. (2018). The Effect of Chronic Diffuse Liver Pathology on the Risk of